

NOVO NORDISK A S
Form 6-K
April 13, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

APRIL 13, 2010

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

**Novo Allé
DK- 2880, Bagsvaerd
Denmark**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

12 April 2010

Novo Nordisk A/S – Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.

Since the announcement as of 6 April 2010, the following transactions have been made under the programme:

	Number of	Average Transaction value,	
	shares	purchase price	DKK
Accumulated, last	3,710,000		1,486,757,438
announcement			
6 April 2010	50,000	440.7300	22,036,500
7 April 2010	60,000	444.1860	26,651,160
8 April 2010	70,000	439.1500	30,740,500
9 April 2010	150,000	434.7568	65,213,520
Accumulated under	4,040,000		1,631,399,118

the programme

With the transactions stated above, Novo Nordisk owns a total of 34,311,298 treasury shares, corresponding to 5.5% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Company Announcement no 20 / 2010

Page 1 of 2

Novo Nordisk A/S	Novo Allé	Telephone:	Internet:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	novonordisk.com	24256790
	Denmark	Telefax:		
		+45 4444 6626		

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Investors:

Mette Kruse Danielsen Klaus Bülow Davidsen

Tel: (+45) 4442 3883 Tel: (+45) 4442 3176

mkd@novonordisk.com klda@novonordisk.com

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

krop@novonordisk.com

In North America:

In North America:

Sean Clements Hans Rommer

Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937

secl@novonordisk.com hrrm@novonordisk.com

Company Announcement no 20 / 2010

Page 2 of 2

Novo Nordisk A/S	Novo Allé	Telephone:	Internet:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	novonordisk.com	24256790
	Denmark	Telefax:		
		+45 4444 6626		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: APRIL 13, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer
